Premium
Sterol regulatory element–binding protein‐1c and pancreatic β‐cell dysfunction
Author(s) -
Shimano H.,
AmemiyaKudo M.,
Takahashi A.,
Kato T.,
Ishikawa M.,
Yamada N.
Publication year - 2007
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/j.1463-1326.2007.00779.x
Subject(s) - lipotoxicity , medicine , endocrinology , lipogenesis , sterol regulatory element binding protein , insulin resistance , biology , beta cell , insulin , saturated fatty acid , chemistry , fatty acid , lipid metabolism , sterol , islet , cholesterol , biochemistry
It has long been known that excess intracellular fatty acids cause impaired insulin secretion, referred to as β‐cell lipotoxicity. Sterol regulatory element–binding protein (SREBP)‐1c is a transcription factor that controls hepatic fatty acid synthesis. Activation of SREBP‐1c by overnutrition also inhibits insulin receptor substrate‐2 (IRS‐2) and induces insulin resistance in the liver. As SREBP‐1c is also expressed in β cells, we hypothesized that activation of SREBP‐1c could be a part of the mechanism by which saturated fatty acids induce β‐cell lipotoxicity. We found that nuclear SREBP‐1c has a negative impact on both glucose‐ and potassium‐stimulated insulin secretion as determined in islets from β‐cell‐specific SREBP‐1c transgenic mice as well as SREBP‐1c knockout mice. This effect of SREBP‐1c involves multiple functional pathways required for insulin secretion from β cells: (i) decreased ATP caused by energy consumption through lipogenesis and uncoupling protein‐2 (UCP‐2) activation; (ii) repressed IRS‐2 and pancreas duodenum homeobox 1 (PDX1) expression, leading to impaired β‐cell mass; and (iii) impaired post‐ATP membrane voltage–dependent steps of the insulin secretion pathway caused by upregulated granuphilin and other ion channel proteins. Saturated fatty acids, such as palmitic acid (PA), impair insulin secretion through SREBP‐1c activation, whereas polyunsaturated fatty acids including eicosapentaenoic acid (EPA) restore PA‐suppressed insulin secretion through suppression of SREBP‐1c. These data implicate a therapeutic potential of EPA against insulin secretion defects caused by lipotoxicity.